Letter to the Editor: Rifamycin SV MMX was superior to placebo, but was the comparison appropriate?
- PMID: 39023341
- PMCID: PMC11262814
- DOI: 10.1097/HC9.0000000000000470
Letter to the Editor: Rifamycin SV MMX was superior to placebo, but was the comparison appropriate?
Conflict of interest statement
The authors have no conflicts to report.
Comment on
-
The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathy.Hepatol Commun. 2024 Feb 3;8(2):e0384. doi: 10.1097/HC9.0000000000000384. eCollection 2024 Feb 1. Hepatol Commun. 2024. PMID: 38315140 Free PMC article. Clinical Trial.
References
-
- Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109–117. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
